OtherResearch Market

Prostamax

A synthetic tetrapeptide (Lys-Glu-Asp-Pro) from the Khavinson bioregulator family, studied for prostatic tissue bioregulation and geroprotective effects.

ProstateMen's HealthBioregulatorKhavinson

Also referenced as: KEDP, Lys-Glu-Asp-Pro

Also appears in: Longevity

Price compare
20 tracked offers across 20 vendors · 10 dosages
Best trust-adjusted value: Peptide Supply Co · Strong trust · $1.89/mg
From
$1.78/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Aug 10
Current low$1.89/mg
Market median$2.25/mg
Current coverage6 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Prostamax crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence12 certificate records mentioning this compound or product name4 provider-linked · 12 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Other research areas

Primary research area: Other. Also surfaces under Longevity for browsing and discovery.

Aliases
2

KEDP, Lys-Glu-Asp-Pro

Signal depth
Low

No FDA label signal · 0 trials · 9 PubMed results

Preclinical
Research evidence

Current evidence for Prostamax is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Prostamax has no clinical trials that name it and 9 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
Established
International Journal of Molecular Sciences · 17 citationsInvestigating the Role of FABP4 in Diabetes and Obesity and the Influence of Age and Ethnicity: A Comprehensive Analysis of a Cohort from the KEDP-StudyModern Research in Inflammation · 1 citationsExperimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complicationsPubMed · 1 citations[Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)].Journal ArticleFeasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters.Journal ArticleThe interaction of amino acids, peptides, and proteins with DNA.Journal ArticleChinese medicine patterns in patients with post-stroke dementia.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is Prostamax?

Prostamax is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Pro (KEDP), developed as part of Vladimir Khavinson’s bioregulator peptide program at the Saint Petersburg Institute of Bioregulation and Gerontology. It is classified as a prostate-tissue bioregulator within the Khavinson framework of organ-specific short peptides.

How it works

The proposed mechanism follows the Khavinson bioregulation model:

  • Tissue-specific gene regulation — short peptides are theorized to penetrate cell nuclei and interact with gene promoter regions in a tissue-specific manner, modulating transcription of genes relevant to prostatic function (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
  • Geroprotective effects — bioregulator peptide preparations targeting various organs have been associated with improved tissue function in aged animals and reduced age-related pathology (Khavinson, Gerontology, 2005)

Research status

  • Khavinson (2005) reviewed 35 years of peptide bioregulator research including organ-specific peptides (Gerontology, 51(2):70–75)
  • Khavinson & Malinin (2005) described the theoretical framework for tissue-specific short peptide bioregulation (Neuroendocrinology Letters, 26(3):233–238)
  • Published clinical data specific to Prostamax is limited to Russian-language literature from the Khavinson group

Key considerations

  • Part of the Khavinson bioregulator family alongside Pinealon, Cartalax, Epitalon, and others — same research group, same proposed mechanism, different target tissues
  • No independent Western replication studies or peer-reviewed clinical trials
  • Available from research vendors as lyophilized powder or capsules (typically 10–20mg)